Druggability of Intrinsically Disordered Proteins.
暂无分享,去创建一个
[1] C. Chothia,et al. The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.
[2] R. Pappu,et al. Versatility from Protein Disorder , 2012, Science.
[3] Chi V. Dang,et al. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.
[4] Christopher J. Oldfield,et al. Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners , 2008, BMC Genomics.
[5] Michele Vendruscolo,et al. Chemical kinetics for drug discovery to combat protein aggregation diseases. , 2014, Trends in pharmacological sciences.
[6] Kurt Wüthrich,et al. Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.
[7] Kunal Patel,et al. De novo design of self-assembled hexapeptides as β-amyloid (Aβ) peptide inhibitors. , 2014, ACS chemical neuroscience.
[8] T. Blundell,et al. Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.
[9] Sara Linse,et al. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides , 2014, Proceedings of the National Academy of Sciences.
[10] C. Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.
[11] P. Chène,et al. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.
[12] Michele Vendruscolo,et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril , 2013, Proceedings of the National Academy of Sciences.
[13] A Keith Dunker,et al. Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. , 2010, Current opinion in pharmacology.
[14] Christopher J. Oldfield,et al. Classification of Intrinsically Disordered Regions and Proteins , 2014, Chemical reviews.
[15] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[16] Marc S. Cortese,et al. Rational drug design via intrinsically disordered protein. , 2006, Trends in biotechnology.
[17] H. Dyson,et al. Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.
[18] M. Blackledge,et al. Structural characterization of flexible proteins using small-angle X-ray scattering. , 2007, Journal of the American Chemical Society.
[19] P. Hajduk,et al. NMR-based screening in drug discovery , 1999, Quarterly Reviews of Biophysics.
[20] J Andrew McCammon,et al. A molecular dynamics ensemble-based approach for the mapping of druggable binding sites. , 2012, Methods in molecular biology.
[21] Binh Vu,et al. Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.
[22] Mathias Jucker,et al. The Amyloid State of Proteins in Human Diseases , 2012, Cell.
[23] István Simon,et al. The expanding view of protein–protein interactions: complexes involving intrinsically disordered proteins , 2011, Physical biology.
[24] Marc-André Delsuc,et al. Biophysical techniques for ligand screening and drug design. , 2009, Current opinion in pharmacology.
[25] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[26] Tuomas P. J. Knowles,et al. The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.
[27] Giovanna Zinzalla,et al. Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. , 2012, Journal of the American Chemical Society.
[28] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[29] D. Teplow,et al. A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis. , 2009, Biochemistry.
[30] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[31] Alexander K. Buell,et al. Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease , 2014, PloS one.
[32] Johannes Buchner,et al. The N-terminal domain of p53 is natively unfolded. , 2003, Journal of molecular biology.
[33] Michele Vendruscolo,et al. Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide. , 2013, The Journal of chemical physics.
[34] S. Jones,et al. Principles of protein-protein interactions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[36] Michele Vendruscolo,et al. Towards complete descriptions of the free–energy landscapes of proteins , 2005, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[37] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[38] J. Michel,et al. The Impact of Small Molecule Binding on the Energy Landscape of the Intrinsically Disordered Protein C-Myc , 2012, PloS one.
[39] T. Clackson,et al. A hot spot of binding energy in a hormone-receptor interface , 1995, Science.
[40] Tuomas P. J. Knowles,et al. An Analytical Solution to the Kinetics of Breakable Filament Assembly , 2009, Science.
[41] Michele Vendruscolo,et al. Determination of conformationally heterogeneous states of proteins. , 2007, Current opinion in structural biology.
[42] D. Svergun,et al. Structural analysis of intrinsically disordered proteins by small-angle X-ray scattering. , 2012, Molecular bioSystems.
[43] Karen H. Vousden,et al. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.
[44] L. Iakoucheva,et al. Intrinsic disorder in cell-signaling and cancer-associated proteins. , 2002, Journal of molecular biology.
[45] JoAnne McLaurin,et al. Small molecule inhibitors of Aβ‐aggregation and neurotoxicity , 2009 .
[46] C. Dobson. The structural basis of protein folding and its links with human disease. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[47] Laurie E. Grove,et al. Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.
[48] Marc S. Cortese,et al. Flexible nets , 2005, The FEBS journal.
[49] Michael H. Hecht,et al. A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation , 2012, The Journal of Biological Chemistry.
[50] Matthew E Welsch,et al. Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.
[51] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[52] Philip J. Hajduk,et al. Fragment-based lead discovery: challenges and opportunities , 2011, J. Comput. Aided Mol. Des..
[53] A Keith Dunker,et al. Unfoldomics of human diseases: linking protein intrinsic disorder with diseases , 2009, BMC Genomics.
[54] C. Dobson. Chemical space and biology , 2004, Nature.
[55] Horst Kessler,et al. NMR-based screening: a powerful tool in fragment-based drug discovery. , 2007 .
[56] P. Imming,et al. Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.
[57] Dmitri I. Svergun,et al. pE-DB: a database of structural ensembles of intrinsically disordered and of unfolded proteins , 2013, Nucleic Acids Res..
[58] L. Poppe,et al. Ordering of the N-terminus of human MDM2 by small molecule inhibitors. , 2012, Journal of the American Chemical Society.
[59] V. Uversky. Unusual biophysics of intrinsically disordered proteins. , 2013, Biochimica et biophysica acta.
[60] Ariele Viacava Follis,et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. , 2009, Journal of the American Chemical Society.
[61] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[62] Martin Blackledge,et al. Intrinsically Disordered Proteins: From Sequence and Conformational Properties toward Drug Discovery , 2012, Chembiochem : a European journal of chemical biology.
[63] Dmitri I. Svergun,et al. Low-resolution structures of transient protein-protein complexes using small-angle X-ray scattering. , 2009, Journal of the American Chemical Society.
[64] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[65] Wendy A. Warr,et al. Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..
[66] Liling Zhao,et al. Novel Strategies for Drug Discovery Based on Intrinsically Disordered Proteins (IDPs) , 2011, International journal of molecular sciences.
[67] P. Tompa,et al. Introducing protein intrinsic disorder. , 2014, Chemical reviews.
[68] C. Dobson,et al. Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.
[69] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[70] Christopher J. Oldfield,et al. Intrinsically disordered proteins in human diseases: introducing the D2 concept. , 2008, Annual review of biophysics.
[71] S. Metallo,et al. Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.
[72] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[73] Yanli Wang,et al. PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..
[74] V. Uversky,et al. Intrinsic Disorder in PTEN and its Interactome Confers Structural Plasticity and Functional Versatility , 2013, Scientific Reports.
[75] P. Tompa. Intrinsically disordered proteins: a 10-year recap. , 2012, Trends in biochemical sciences.
[76] Michele Vendruscolo,et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism , 2013, Proceedings of the National Academy of Sciences.
[77] L. Iakoucheva,et al. Intrinsic Disorder and Protein Function , 2002 .
[78] Vladimir N Uversky,et al. Intrinsically disordered proteins and novel strategies for drug discovery , 2012, Expert opinion on drug discovery.
[79] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[80] Harald Schwalbe,et al. Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.
[81] Ehud Gazit,et al. Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism , 2006, Chemical biology & drug design.
[82] R. Kayed,et al. Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.